Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer

Alessio Nencioni, Martin R. Müller, Frank Grünebach, Anna Garuti, Maria C. Mingari, Franco Patrone, Alberto Ballestrero, Peter Brossart

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Dendritic cells (DC) are the most potent antigen-presenting cells known, currently tested for vaccination studies in cancer patients. The use of tumor-derived RNA to load DC overcomes the requirement of defined HLA types and the identification of tumor antigens expressed by the tumors. Here, we show that human monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-α acquire a mature phenotype and expression of the chemokine receptor CCR-7, which plays a pivotal role in DC migration to the afferent lymph nodes. We demonstrate the feasibility of total RNA transfection into such DC using the renal cell carcinoma (RCC) cell line N43-EGFP, which was stably transfected with an EGFP-encoding vector. Moreover, we show that DC transfected with RNA from colorectal cancer cells present HLA class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. Interestingly, the CTL induced by SW480 RNA also recognized another colon cancer line, HCT116, and the RCC line A498. Our results confirm the feasibility of total RNA transfection of serum-free generated DC for the induction of CTL against colon cancer and RCC cells, and support the relevance of shared tumor rejection epitopes between colorectal cancer and RCC.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalCancer Gene Therapy
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 1 2003

Fingerprint

Dendritic Cells
Colorectal Neoplasms
RNA
Renal Cell Carcinoma
Neoplasms
Colonic Neoplasms
Transfection
Epitopes
HCT116 Cells
Cell Line
Chemokine Receptors
Neoplasm Antigens
Antigen-Presenting Cells
Granulocyte-Macrophage Colony-Stimulating Factor
Serum
Interleukin-4
Cell Movement
Monocytes
Vaccination
Lymph Nodes

Keywords

  • Colorectal cancer
  • Cytotoxic T. lymphocytes
  • Dendritic cells
  • RNA transfection

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. / Nencioni, Alessio; Müller, Martin R.; Grünebach, Frank; Garuti, Anna; Mingari, Maria C.; Patrone, Franco; Ballestrero, Alberto; Brossart, Peter.

In: Cancer Gene Therapy, Vol. 10, No. 3, 01.03.2003, p. 209-214.

Research output: Contribution to journalArticle

Nencioni, Alessio ; Müller, Martin R. ; Grünebach, Frank ; Garuti, Anna ; Mingari, Maria C. ; Patrone, Franco ; Ballestrero, Alberto ; Brossart, Peter. / Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. In: Cancer Gene Therapy. 2003 ; Vol. 10, No. 3. pp. 209-214.
@article{53dcf56b24c849228a98834b27bef225,
title = "Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer",
abstract = "Dendritic cells (DC) are the most potent antigen-presenting cells known, currently tested for vaccination studies in cancer patients. The use of tumor-derived RNA to load DC overcomes the requirement of defined HLA types and the identification of tumor antigens expressed by the tumors. Here, we show that human monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-α acquire a mature phenotype and expression of the chemokine receptor CCR-7, which plays a pivotal role in DC migration to the afferent lymph nodes. We demonstrate the feasibility of total RNA transfection into such DC using the renal cell carcinoma (RCC) cell line N43-EGFP, which was stably transfected with an EGFP-encoding vector. Moreover, we show that DC transfected with RNA from colorectal cancer cells present HLA class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. Interestingly, the CTL induced by SW480 RNA also recognized another colon cancer line, HCT116, and the RCC line A498. Our results confirm the feasibility of total RNA transfection of serum-free generated DC for the induction of CTL against colon cancer and RCC cells, and support the relevance of shared tumor rejection epitopes between colorectal cancer and RCC.",
keywords = "Colorectal cancer, Cytotoxic T. lymphocytes, Dendritic cells, RNA transfection",
author = "Alessio Nencioni and M{\"u}ller, {Martin R.} and Frank Gr{\"u}nebach and Anna Garuti and Mingari, {Maria C.} and Franco Patrone and Alberto Ballestrero and Peter Brossart",
year = "2003",
month = "3",
day = "1",
doi = "10.1038/sj.cgt.7700557",
language = "English",
volume = "10",
pages = "209--214",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer

AU - Nencioni, Alessio

AU - Müller, Martin R.

AU - Grünebach, Frank

AU - Garuti, Anna

AU - Mingari, Maria C.

AU - Patrone, Franco

AU - Ballestrero, Alberto

AU - Brossart, Peter

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Dendritic cells (DC) are the most potent antigen-presenting cells known, currently tested for vaccination studies in cancer patients. The use of tumor-derived RNA to load DC overcomes the requirement of defined HLA types and the identification of tumor antigens expressed by the tumors. Here, we show that human monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-α acquire a mature phenotype and expression of the chemokine receptor CCR-7, which plays a pivotal role in DC migration to the afferent lymph nodes. We demonstrate the feasibility of total RNA transfection into such DC using the renal cell carcinoma (RCC) cell line N43-EGFP, which was stably transfected with an EGFP-encoding vector. Moreover, we show that DC transfected with RNA from colorectal cancer cells present HLA class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. Interestingly, the CTL induced by SW480 RNA also recognized another colon cancer line, HCT116, and the RCC line A498. Our results confirm the feasibility of total RNA transfection of serum-free generated DC for the induction of CTL against colon cancer and RCC cells, and support the relevance of shared tumor rejection epitopes between colorectal cancer and RCC.

AB - Dendritic cells (DC) are the most potent antigen-presenting cells known, currently tested for vaccination studies in cancer patients. The use of tumor-derived RNA to load DC overcomes the requirement of defined HLA types and the identification of tumor antigens expressed by the tumors. Here, we show that human monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-α acquire a mature phenotype and expression of the chemokine receptor CCR-7, which plays a pivotal role in DC migration to the afferent lymph nodes. We demonstrate the feasibility of total RNA transfection into such DC using the renal cell carcinoma (RCC) cell line N43-EGFP, which was stably transfected with an EGFP-encoding vector. Moreover, we show that DC transfected with RNA from colorectal cancer cells present HLA class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. Interestingly, the CTL induced by SW480 RNA also recognized another colon cancer line, HCT116, and the RCC line A498. Our results confirm the feasibility of total RNA transfection of serum-free generated DC for the induction of CTL against colon cancer and RCC cells, and support the relevance of shared tumor rejection epitopes between colorectal cancer and RCC.

KW - Colorectal cancer

KW - Cytotoxic T. lymphocytes

KW - Dendritic cells

KW - RNA transfection

UR - http://www.scopus.com/inward/record.url?scp=0037345749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037345749&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700557

DO - 10.1038/sj.cgt.7700557

M3 - Article

C2 - 12637942

AN - SCOPUS:0037345749

VL - 10

SP - 209

EP - 214

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 3

ER -